KCT0000494已完成未知
A Randomized Double-Blind Placebo-Controlled Trial of efficacy of phloroglucinol in Irritable Bowel Syndrome
Chung-Ang Univerisity Hospital0 个研究点目标入组 72 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 72
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 20(Year) 至 65(Year)（—）
- 性别
- All
入选标准
- •1) The patients with diarrhea-dominant IBS (D-IBS) consented by ROME III.
- •2) The patients who had no organic bowel disease in the colonoscopy or Ba-enema performed within 5 years.
- •3) The patients who consented this trial.
排除标准
- •1) The patients who were allergic to fluoroglucin.
- •2) The patients who received abdominal operation except appendectomy and hernioplasty
- •3) The patients who have the diseases that might affect the assessment of drug efficacy, such as IBD and colon cancer.
- •4) The patients who take medication that might affect the assessment of drug efficacy, such as IBD and colon cancer.
- •5) The patients with glaucoma or prostate hypertrophy
- •6) The patients who have severe medical disease, such as liver cirrhosis, congestive heart failure, and chronic renal failure.
- •7) Prangnant or lactating patients
研究者
相似试验
已完成
4 期
Effect of Vitamin D3 on Functions of Kidney and Blood Vessels in Vitamin D Deficient Patients with Type 2 Diabetes MellitusCTRI/2017/12/010785Intramural fund100
进行中（未招募）
1 期
eratinib adjuvant studyEUCTR2008-007345-31-LTPuma Biotechnology, Inc2,842
进行中（未招募）
1 期
eratinib adjuvant studyEUCTR2008-007345-31-BEPuma Biotechnology, Inc2,842
进行中（未招募）
1 期
A Randomized Double-blind Placebo-Controlled Trial of Neratinib (HKI-272) After Trastuzumab in Women With Early-Stage HER-2/neu Overexpressed/Amplified Breast Cancer. Ensayo aleatorizado, en doble ciego y controlado con placebo, de neratinib (HKI-272) después de trastuzumab en mujeres con cáncer de mama en estadío inicial con sobreexpresión/amplificación de HER-2/neuEUCTR2008-007345-31-ESWyeth Research, Division of Wyeth Pharmaceuticals, Inc.3,850
进行中（未招募）
1 期
A Randomized Double-blind Placebo-Controlled Trial of Neratinib (HKI-272) After Trastuzumab in Women With Early-Stage HER-2/neu Overexpressed/Amplified Breast Cancer.Her2 overexpressed, early stage breast cancer (adjuvant treatment stage)MedDRA version: 9.1Level: LLTClassification code 10006173Term: Breast adenocarcinomaEUCTR2008-007345-31-GRWyeth Research, Division of Wyeth Pharmaceuticals, Inc.3,850